Clinical Trials Sponsored by Affectis Pharmaceuticals AG

Total 51 results

Affectis Pharmaceuticals AG
FGK Clinical Research GmbH

Completed

Cimicoxib for the Treatment of Major Depression (SECIM)

Major Depression

Austria, Czech Republic, Germany
T3 Pharmaceuticals AG

Recruiting

First in Human Study of T3P-Y058-739 (T3P)

Advanced Solid Tumor

United Kingdom, Switzerland
Polyneuron Pharmaceuticals AG

Terminated

First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy

Anti-MAG Neuropathy

Spain, France, Netherlands, Switzerland, United Kingdom
Phenex Pharmaceuticals AG

Completed

Single Ascending Oral Dose Phase I Study With Px-102

Healthy

Germany
Phenex Pharmaceuticals AG

Completed

Multiple Ascending Oral Dose Phase I Study With Px-102

Healthy

Germany
Bows Pharmaceuticals AG

Suspended

A Study to Determine the Absorption of Peroral Insulin in Dextran Matrix (ORA3) (ORA3)

Diabetes Mellitus

Sweden
Bows Pharmaceuticals AG

Suspended

A Two Part Study of Peroral Insulin in Type 2 Diabetes (ORA2)

Diabetes Mellitus

Sweden
AOP Orphan Pharmaceuticals AG

Not yet recruiting

Investigational Trial to Evaluate Safety and Tolerability of Treprostinil in Children Diagnosed With PAH

Pulmonary Arterial Hypertension

Spain, Austria, France, Hungary
AOP Orphan Pharmaceuticals AG

Completed

A Short Term Pharmacokinetic, Pharmacodynamic and Tolerability Study to Compare AOP200704 vs. Esmolol

Healthy Volunteers | Pharmacokinetics/Dynamics Study

Czech Republic
iOMEDICO AG
Novartis Pharmaceuticals

Completed

First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma (FLIPPER)

Carcinoma, Renal Cell | Clear-cell Metastatic Renal Cell Carcinoma | Locally Advanced and/or Metastatic Renal Cell Carcinoma

Germany
AOP Orphan Pharmaceuticals AG

Completed

A Pharmacokinetic, Pharmacodynamic, Safety Study With AOP LDLA202, ONO LDL50 and Esmolol in Healthy Volunteers

Healthy

Czech Republic
AOP Orphan Pharmaceuticals AG

Completed

Lancovutide (Moli1901) Inhalation Solution Study in Adolescents and Adults With Cystic Fibrosis

Cystic Fibrosis

Austria
iOMEDICO AG
Novartis Pharmaceuticals

Completed

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line (RIBBIT)

Breast Cancer | Hormone Receptor Positive Tumor | HER 2 Negative Breast Cancer

Germany
AOP Orphan Pharmaceuticals AG

Completed

Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera (PEGINVERA)

Polycythemia Vera

Austria
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia (ARETA)

Essential Thrombocythaemia

Poland, Slovakia, Bulgaria, Russian Federation, Romania, Croatia, Lithuania, Austria, Ukraine
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide Retard in Essential Thrombocythemia (TEAM-ET)

Essential Thrombocythemia

Austria, Bulgaria, Lithuania, Poland, Russian Federation
AOP Orphan Pharmaceuticals AG

Completed

Long-term PK and Safety/Tolerability Testing LDLL600 Against Esmolol in Healthy Volunteers

Healthy

Czech Republic
AOP Orphan Pharmaceuticals AG

Completed

Anagrelide vs. Hydroxyurea - Efficacy and Tolerability Study in Patients With Essential Thrombocythaemia (ANAHYDRET)

Essential Thrombocythaemia

Austria, Czech Republic, France, Germany, Hungary, Italy, Lithuania, Poland, Singapore, Slovenia
Syndax Pharmaceuticals
Roche Pharma AG

Completed

Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In

Breast Cancer

United States, Georgia
Tillotts Pharma AG
Zeria Pharmaceutical

Completed

Comparative Efficacy and Safety Study in Patients With Active Ulcerative Colitis

Active Ulcerative Colitis

China
Tillotts Pharma AG
Zeria Pharmaceutical

Completed

Comparative Efficacy and Safety Study in Patients With Ulcerative Colitis in Remission Phase

Ulcerative Colitis in Remission

China
Novartis Pharmaceuticals
Molecular Partners AG

Terminated

A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19 (EMPATHY)

COVID-19

United States, India, Hungary, Netherlands, South Africa
Novartis Pharmaceuticals
Roche Pharma AG

Completed

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Adenocarcinoma | Carcinoma | Renal Cell | Nephroid Carcinoma | Hypernephroid

Belgium, Italy, Spain, United Kingdom, Germany, Taiwan, Turkey, Egypt, Hong Kong, Russian Federation, Switzerland, Thailand, France, Netherlands, Korea, Republic of, Brazil, United States, Czech Republic, South Africa, Hungary, ...
Infinity Pharmaceuticals, Inc.
Roche Pharma AG

Active, not recruiting

Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)

Renal Cell Carcinoma | Breast Cancer

United States
Aspireo Pharmaceuticals Limited
DeveloGen AG, Germany

Completed

Single Ascending Dose Tolerability Study of DG3173

Healthy
Arbeitsgemeinschaft medikamentoese Tumortherapie
AOP Orphan Pharmaceuticals AG

Completed

Addition of P1101 to Imatinib Treatment in Patients With Chronic Phase Chronic Myeloid Leukaemia Not Achieving a Complete Molecular Response

Chronic Phase Chronic Myeloid Leukemia

Austria
University Hospital, Essen
Novartis Pharmaceuticals; iOMEDICO AG

Completed

Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer (PIKTAM)

Breast Cancer

Germany
AIO-Studien-gGmbH
Novartis Pharmaceuticals; iOMEDICO AG

Completed

Study to Compare Vinorelbine In Combination With the mTOR Inhibitor Everolimus vs. Vinorelbin Monotherapy for Second-line Treatment in Advanced Breast Cancer (VicTORia)

Her2-negative Metastatic Breast Cancer | Her2-negative Locally Advanced Breast Cancer

Germany
Phenex Pharmaceuticals AG
Medical University of Vienna

Completed

Safety Pilot Study of Farnesoid X Receptor (FXR) Agonist in Non-alcoholic Fatty Liver Disease (NAFLD) Patients

Non Alcoholic Fatty Liver Disease

Austria
Numab Therapeutics AG
Kaken Pharmaceutical Co., Ltd.

Recruiting

Evaluation of NM26-2198 in Healthy Subjects and in Patients With Moderate-to-severe Atopic Dermatitis (AD)

Atopic Dermatitis

Germany, Canada, United States, Poland
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
University of Pittsburgh
Roche Pharma AG; Aventis Pharmaceuticals

Terminated

A Study of Docetaxel in Combination With Capecitabine in Stomach and Esophagus Cancers

Cancer

United States
Insel Gruppe AG, University Hospital Bern
Bayer; Janssen Pharmaceuticals

Completed

Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery (BARIVA)

Bariatric Surgery

Switzerland
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (for the U.S.)

Completed

AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. (CONTI-PV)

Polycythemia Vera

Spain, Austria, Bulgaria, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine, Czechia
AOP Orphan Pharmaceuticals AG
PharmaEssentia (Co-Sponsor for USA)

Completed

Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera (PROUD-PV)

Polycythemia Vera

Spain, Belgium, Austria, Italy, Bulgaria, Czech Republic, France, Germany, Hungary, Poland, Romania, Russian Federation, Slovakia, Ukraine
Seoul National University Hospital
Roche Pharma AG; SciClone Pharmaceuticals

Completed

Efficacy Study of Thymosin alpha1 & Pegylated Interferon-alpha2a to Treat Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of
Groupe d'Etude Therapeutique des Affections Inflammatoires...
AbbVie; Gilead Sciences; Roche Pharma AG; Takeda; Celgene; Biogen

Completed

Crohn's Disease Endoscopic REmission Definition in an Objective Way (CREDO1)

CD

Belgium, France
Groupe d'Etude Therapeutique des Affections Inflammatoires...
AbbVie; Gilead Sciences; Roche Pharma AG; Takeda; Celgene; Biogen

Active, not recruiting

Is the Endoscopic Remission Evaluation, Using the CREDO 1 Index / Score in CD Patients in Clinical Remission at Baseline, Predictive of Sustained Clinical Remission Using a 2-year Follow up (CREDO2)

CD

Belgium, France
German Breast Group
GlaxoSmithKline; Roche Pharma AG; Teva Pharmaceuticals USA

Completed

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer (GeparSixto)

Inflammatory Breast Cancer | HER-2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III | Inflammatory Breast Cancer Stage IV

Germany
Sucampo Pharma Americas, LLC
Sucampo AG; Sucampo Pharmaceuticals, Inc.

Completed

Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

Chronic Idiopathic Constipation

United States
Fondazione per la Ricerca Ospedale Maggiore
AOP Orphan Pharmaceuticals AG

Completed

The Benefit/Risk Profile of AOP2014 in Low-risk Patients With PV (Low-PV)

Polycythemia Vera

Italy
AOP Orphan Pharmaceuticals AG
PharmaEssentia Corporation (Co-Sponsor for USA)

Completed

Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients (PEN-PV)

Polycythemia Vera

Austria, Bulgaria, Czech Republic, France, Hungary, Poland, Slovakia, Ukraine
German Breast Group
Roche Pharma AG; Amgen; Teva Pharmaceuticals USA; Vifor Pharma

Completed

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Inflammatory Breast Cancer | HER2 Positive Breast Cancer | Tubular Breast Cancer Stage II | Mucinous Breast Cancer Stage II | Breast Cancer Female NOS | Invasive Ductal Breast Cancer | Tubular Breast Cancer Stage III

Germany
Philipps University Marburg Medical Center
Deutsche Krebshilfe e.V., Bonn (Germany); AOP Orphan Pharmaceuticals AG

Completed

ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission (ENDURE-CML-IX)

Chronic Myeloid Leukemia in Remission

France, Germany
Prof. W. Janni
Roche Pharma AG; Novartis Pharmaceuticals; Celgene Corporation; Eisai GmbH

Recruiting

Detect V / CHEVENDO (Chemo vs. Endo)

Metastatic Breast Cancer

Germany
AOP Orphan Pharmaceuticals AG
GCP-Service International Ltd. & Co. KG; ANOVA CRO s.r.o.; PharmaLex Belgium; Aixial...

Recruiting

Initial Triple Therapy Including Parenteral Treprostinil vs Initial Double Oral Therapy in PAH Group I Patients (TripleTRE)

Pulmonary Arterial Hypertension

Austria, Spain, France, Germany, Italy, Czechia, Hungary, Poland, Portugal, Romania
Vall d'Hebron Institute of Oncology
Taisho Pharmaceutical Co., Ltd.; Roche Pharma AG; Iqvia Pty Ltd; Janssen, LP

Recruiting

A Modular Multi-Basket Trial to Improve Personalized Medicine in Cancer Patients (Basket of Baskets) (BoB)

Advanced Solid Tumor

Spain, France, Germany, Netherlands, Sweden, United Kingdom, Italy
AIO-Studien-gGmbH
Bristol-Myers Squibb; Eli Lilly and Company; Merck Sharp & Dohme LLC; Pfizer; Gilead... and other collaborators

Recruiting

Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients (CRISP)

Small-cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage I | Metastatic Non-small Cell Lung Cancer (NSCLC) | Non Small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer Stage II

Germany
Research Center for Clinical Neuroimmunology and...
Hoffmann-La Roche; Novartis Pharmaceuticals; University Hospital, Basel, Switzerland and other collaborators

Recruiting

DreaMS - Validation Study 1

Multiple Sclerosis

Switzerland
Swiss GO Trial Group
Hoffmann-La Roche; Novartis Pharmaceuticals; AGO Study Group; Anticancer Fund,... and other collaborators

Recruiting

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO) (MATAO)

Fallopian Tube Neoplasms | Peritoneal Neoplasms | Ovarian Neoplasm Epithelial | High-grade Serous Ovarian Carcinoma (HGSOC) | Low-grade Serous Ovarian Carcinoma (LGSOC) | Ovarian Endometrioid Carcinoma

Austria, Switzerland, Germany

Clinical Trials Sponsored by Affectis Pharmaceuticals AG

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bahrain

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations